What Are the Important Drug Use Errors in Dialysis Patients?: Pharmacokinetic and Pharmacodynamic Principles

Seminars in Dialysis

Volumn 23, Issue 5, 2010, Pages 466-469

  Dager, William E ^a  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

BIOAVAILABILITY; CHRONIC KIDNEY FAILURE; DOSE CALCULATION; DOSE RESPONSE; DRUG MONITORING; HUMAN; MEDICATION ERROR; METABOLISM; METHODOLOGY; NOTE; PHARMACOKINETICS; RENAL REPLACEMENT THERAPY; THEORETICAL MODEL;

BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICATION ERRORS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RENAL DIALYSIS;

EID: 78049440484     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00773.x     Document Type: Note

References (17)

1. Dager WE, King JH: Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother 40:9-14, 2006
2. Kielstein JT, Czock D, Schöpke T, Hafer C, Bode-Böger SM, Kuse E, Keller F, Fliser D: Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 34:51-56, 2006
3. Dager WE: Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis. Crit Care Med 34:240-241, 2006
4. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA: Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol Dial Transplant 25:1279-1284, 2010
5. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX: Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 105:225-231, 2002
6. Verbeeck RK, Musuamba FT: Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65:757-773, 2009
7. Nolan T: Clinical implications of metabolic alterations in end stage renal disease. Semin Dial (inpress)
8. Ding F, Humes HD: The bioartificial kidney and bioengineered membranes in acute kidney injury. Nephron Exp Nephrol 109:e118-e122, 2008
9. Anne L, Hu M, Chan K, Colin L, Gottwald K: Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit 11:585-591, 1989
10. Kingery JR, Sowinski KM, Kraus MA, Klaunig JE, Mueller BA: Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis. Pharmacotherapy 20:653-656, 2000
11. Kinniburgh DW, Boyd ND: Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins. Clin Pharmacol Ther 30:276-280, 1981
12. Mauro LS, Mauro VF, Bachmann KA, Higgins JT: Accuracy of two equations in determining normalized phenytoin concentrations. DICP 23:64-68, 1989
13. Roberts WL, De BK, Coleman JP, Annesley TM: Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin. Clin Chem 45(6 Pt 1):829-837, 1999
14. Roberts WL, Rainey PM: Phenytoin overview - metabolite interference in some immunoassays could be clinically important. Arch Pathol Lab Med 128:734, 2004
15. Dager WE: Phenytoin assay errors in uremia. Ann Pharmacother 36:939-940, 2002
16. Tutor-Crespo MJ, Hermida J, Tutor JC: Phenytoin immunoassay measurements in serum creatinine samples for patients with renal insufficiency: comparison with high-performance liquid chromatography. J Clin Lab Anal 21:119-123, 2007
17. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L: Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 331:263, 2005